多西他赛治疗去势抵抗性前列腺癌时代,无转移生存作为局限性前列腺癌总生存替代终点的验证
ICECaP-2研究纳入14项试验的15164例个体患者数据,70%患者于2004年后接受治疗,中位随访8.3年。患者水平MFS与OS的Kendall tau为0.92,试验水平5年MFS预测8年OS的R²为0.73(95%CI 0.53-0.82),log(HR)-MFS预测log(HR)-OS的R²为0.83(95%CI 0.64-0.89),OS的替代阈值效应为MFS的HR 0.81。结论认为在更当代的治疗背景下MFS仍是OS的有效替代终点。
要点
- ICECaP-2纳入14项试验15164例个体患者数据,70%于2004年后治疗,中位随访8.3年。
- 患者水平MFS与OS的Kendall tau为0.92,试验水平5年MFS预测8年OS的R²为0.73(95%CI 0.53-0.82)。
- log(HR)-MFS预测log(HR)-OS的R²为0.83(95%CI 0.64-0.89),OS的替代阈值效应为MFS的HR 0.81。
核心结论
- 在患者有更多机会获得多西他赛和其他系统治疗的更当代背景下,MFS仍是OS的有效替代终点。
- 这支持将MFS作为正在进行的局限性前列腺癌辅助试验的主要结局指标。
研究设计与样本
- ICECaP-2纳入ICECaP-1发表后并提供个体患者数据的试验,评估局限性前列腺癌的辅助或挽救治疗,且收集MFS和OS数据。
- 共纳入14项试验的15164例个体患者数据,其中70%的患者于2004年后接受治疗。
- MFS定义为远处转移或任何原因死亡,OS定义为任何原因死亡。
- 采用荟萃分析两阶段验证模型评估替代性,预先定义R²≥0.7为临床相关。
主要发现
- ICECaP-2中位随访8.3年,转移后中位生存为3.1年,而ICECaP-1为1.9年。
- 替代条件1:患者水平MFS与OS的Kendall tau为0.92,试验水平8年OS对5年MFS加权线性回归的R²为0.73(95%CI 0.53-0.82)。
- 替代条件2:log(HR)-OS对log(HR)-MFS加权线性回归的R²为0.83(95%CI 0.64-0.89)。
- OS的替代阈值效应为MFS的HR 0.81。
关键数值与推荐
- 预先定义R²≥0.7为临床相关。
- 患者水平MFS与OS的Kendall tau为0.92。
- 试验水平8年OS对5年MFS加权线性回归的R²为0.73(95%CI 0.53-0.82)。
- log(HR)-OS对log(HR)-MFS加权线性回归的R²为0.83(95%CI 0.64-0.89)。
- OS的替代阈值效应为MFS的HR 0.81。
临床怎么用
- 作者结论认为MFS仍是OS的有效替代终点,支持将MFS作为正在进行的局限性前列腺癌辅助试验的主要结局指标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prior work from the Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) consortium (ICECaP-1) demonstrated that metastasis-free survival (MFS) is a valid surrogate for overall survival (OS) in localized prostate cancer (PCa). This was based on data from patients treated predominantly before 2004, prior to docetaxel being available for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). We sought to validate surrogacy in a more contemporary era (ICECaP-2) with greater availability of docetaxel and other systemic therapies for mCRPC. PATIENTS AND METHODS: Eligible trials for ICECaP-2 were those providing individual patient data (IPD) after publication of ICECaP-1 and evaluating adjuvant/salvage therapy for localized PCa, and which collected MFS and OS data. MFS was defined as distant metastases or death from any cause, and OS was defined as death from any cause. Surrogacy was evaluated using a meta-analytic two-stage validation model, with an R2 ≥ 0.7 defined a priori as clinically relevant. RESULTS: A total of 15 164 IPD from 14 trials were included in ICECaP-2, with 70% of patients treated after 2004. The median follow-up was 8.3 years and the median postmetastasis survival was 3.1 years in ICECaP-2, compared with 1.9 years in ICECaP-1. For surrogacy condition 1, Kendall's tau was 0.92 for MFS with OS at the patient level, and R2 from weighted linear regression (WLR) of 8-year OS on 5-year MFS was 0.73 (95% confidence interval 0.53-0.82) at the trial level. For condition 2, R2 was 0.83 (95% confidence interval 0.64-0.89) from WLR of log[hazard ratio (HR)]-OS on log(HR)-MFS. The surrogate threshold effect on OS was an HR(MFS) of 0.81. CONCLUSIONS: MFS remained a valid surrogate for OS in a more contemporary era, where patients had greater access to docetaxel and other systemic therapies for mCRPC. This supports the use of MFS as the primary outcome measure for ongoing adjuvant trials in localized PCa.
引用
- Xie W, Ravi P, Buyse M, et al. Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer. Ann Oncol. 2023. PMID: 38061427. doi:10.1016/j.annonc.2023.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。